ENSC Ensysce Biosciences, Inc.
USHealthcareAs of 2026-07-09 16:00
Why ENSC matters now
Ensysce Biosciences, Inc. (ENSC) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.28 with +0.73% on the session and $2.6M in market capitalization; recent performance reads 1-month -8.44% and YTD -70.51%.
The latest financial table shown here is Q1 2026, with revenue of $961.0K, net income of $-3.6M, and EPS of $-0.52. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -386.3%.
The latest indexable market news headline is "Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study" from Accesswire.
Additional event context on this page matters because analyst consensus is available with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-5.46
P/S
0.53
EV/EBITDA
-0.25
DCF Value
$-12,007.47
FCF Yield
-386.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-43.7%
Operating Margin
-251.4%
Net Margin
-250.4%
ROE
-631.5%
ROA
-543.7%
ROIC
2797.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $961.0K | $-3.6M | $-0.52 |
| Q4 2025 | $1.9M | $-2.8M | $-0.51 |
| FY 2025 | $5.1M | $-10.2M | $-3.98 |
| Q3 2025 | $493.1K | $-3.7M | $-1.29 |
Analyst Ratings
Consensus
—
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.84
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.